Dayna Johnson, PhD, MPH, MSW, MS talks about the necessity of community partnerships as the recipient of this year’s Associated Professional Sleep Societies (APSS) Diversity, Equity, and Inclusion Leadership Award at SLEEP 2023 and how inquiring into the community is vital for integrating healthy sleep practices.
Understanding what the community needs when committing to diversity, equity, and inclusion efforts is an integral part to helping communities’ improve their sleep health, explains Dayna Johnson, PhD, MPH, MSW, MS, assistant professor of epidemiology at the Rollins School of Public Health at Emory University in this interview from SLEEP 2023.
Transcript
How important are community partnerships to diversity, equity, and inclusion efforts?
They're absolutely essential. Without community partnerships, we can't do this work. Something that I like to talk a lot about is the lived experience. What we're doing in this research is really informed by what's a priority to the community, and then what's feasible. It's one thing for us to come up with different ways on how to intervene, but if someone is not amenable to those, then it won't be efficient or effective. So, having those partnerships to find out, “what's the priority? How can we partner to make this change?” And then also for us to understand, “what are the factors that are prohibiting sleep for you?”
As an example, from some of my work, we did focus groups around what we formerly referred to as sleep hygiene, which is really just healthy sleep practices, which include sleeping in a dark, quiet room. We had participants say, "I absolutely can't do that. Someone will break into my house if it's dark." That's not something whoever created these thought about. There's nothing around safety, but it's absolutely important. We have to make sure we're finding out, what are the barriers and facilitators and then using those to leverage the work we're doing to make change.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More